BR112014031565A2 - derivado de indanossulfamida inovador - Google Patents

derivado de indanossulfamida inovador Download PDF

Info

Publication number
BR112014031565A2
BR112014031565A2 BR112014031565A BR112014031565A BR112014031565A2 BR 112014031565 A2 BR112014031565 A2 BR 112014031565A2 BR 112014031565 A BR112014031565 A BR 112014031565A BR 112014031565 A BR112014031565 A BR 112014031565A BR 112014031565 A2 BR112014031565 A2 BR 112014031565A2
Authority
BR
Brazil
Prior art keywords
derivative
sulfamide
inden
dihydro
indansulfamide
Prior art date
Application number
BR112014031565A
Other languages
English (en)
Other versions
BR112014031565A8 (pt
BR112014031565B1 (pt
Inventor
Higashiyama Hiroyuki
Sorimachi Keiichi
Saito Minako
Hanada Takahisa
Kosasa Takashi
Teramoto Tetsuyuki
Watanabe Toru
Tanaka Toshiaki
Kita Yoichi
Ishikawa Yukio
Kazuta Yuji
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112014031565A2 publication Critical patent/BR112014031565A2/pt
Publication of BR112014031565A8 publication Critical patent/BR112014031565A8/pt
Publication of BR112014031565B1 publication Critical patent/BR112014031565B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/08—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo “derivado de indanossulfamida inovador” um composto de indanossulfamida inovador, tal como n-[(1s)-2,2,5,7-tetrafluoro-2,3-diidro-1h-inden-1-il]sulfamida, n-[(1s)-2,2,4,7-tetrafluoro-2,3-diidro-1h-inden-1-il]sulfamida, (+)-n- (2,2,4,6,7-pentafluoro-2,3-diidro-1h-inden-1-il)sulfamida, ou um sal farmaceuticamente aceitável dos mesmos tem um efeito de aprimorar a severidade (pontuação) de um ataque em um modelo de kindling de camundongos e, portanto, pode-se esperar que sirva como agente terapêutico para epilepsia.
BR112014031565-5A 2012-06-21 2013-06-17 Derivado de indanossulfamida inovador BR112014031565B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261662626P 2012-06-21 2012-06-21
US61/662.626 2012-06-21
US201261709737P 2012-10-04 2012-10-04
US61/709.737 2012-10-04
US201361751331P 2013-01-11 2013-01-11
US61/751.331 2013-01-11
PCT/JP2013/066623 WO2013191144A1 (ja) 2012-06-21 2013-06-17 新規インダンスルファミド誘導体

Publications (3)

Publication Number Publication Date
BR112014031565A2 true BR112014031565A2 (pt) 2017-06-27
BR112014031565A8 BR112014031565A8 (pt) 2021-06-08
BR112014031565B1 BR112014031565B1 (pt) 2022-04-12

Family

ID=49768740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031565-5A BR112014031565B1 (pt) 2012-06-21 2013-06-17 Derivado de indanossulfamida inovador

Country Status (34)

Country Link
US (1) US9018260B2 (pt)
EP (1) EP2865663B1 (pt)
JP (1) JP5883135B2 (pt)
KR (1) KR101951519B1 (pt)
CN (1) CN104395285B (pt)
AR (1) AR091506A1 (pt)
AU (1) AU2013278450B2 (pt)
BR (1) BR112014031565B1 (pt)
CA (1) CA2877097C (pt)
CL (1) CL2014003429A1 (pt)
CY (1) CY1119171T1 (pt)
DK (1) DK2865663T3 (pt)
ES (1) ES2628374T3 (pt)
HK (1) HK1207363A1 (pt)
HR (1) HRP20170863T1 (pt)
HU (1) HUE033583T2 (pt)
IL (1) IL236295A (pt)
JO (1) JO3263B1 (pt)
LT (1) LT2865663T (pt)
ME (1) ME02753B (pt)
MX (1) MX355261B (pt)
MY (1) MY169073A (pt)
NZ (1) NZ702974A (pt)
PE (1) PE20150284A1 (pt)
PH (1) PH12014502805B1 (pt)
PL (1) PL2865663T3 (pt)
PT (1) PT2865663T (pt)
RS (1) RS56073B1 (pt)
RU (1) RU2619937C2 (pt)
SG (1) SG11201408359PA (pt)
SI (1) SI2865663T1 (pt)
TW (1) TWI597263B (pt)
WO (1) WO2013191144A1 (pt)
ZA (1) ZA201409248B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3043784B9 (en) 2013-09-09 2019-11-20 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
CA2931085C (en) 2013-12-16 2021-10-19 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
CN105792821B (zh) 2013-12-19 2018-05-04 卫材R&D管理有限公司 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
WO2016145032A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
US11660275B2 (en) 2018-03-20 2023-05-30 Eisai R&D Management Co., Ltd. Epilepsy treatment agent
JP2024026905A (ja) * 2020-11-25 2024-02-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 てんかん治療剤
TW202345782A (zh) * 2022-04-27 2023-12-01 日商衛材R&D企管股份有限公司 帕金森氏症治療用醫藥組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3383414A (en) * 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
US3709677A (en) 1969-06-25 1973-01-09 Sandoz Ag N-substituted sulfamoyl compounds useful as herbicides
US6958416B2 (en) * 2001-06-26 2005-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Valproyltaurinamide derivatives as anticonvulsant amd CNS active agents
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
AU2005277134A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
CN100572365C (zh) * 2006-01-26 2009-12-23 全哲山 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
AR070949A1 (es) * 2007-10-19 2010-05-19 Solvay Pharm Gmbh Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
US8633237B2 (en) 2009-04-09 2014-01-21 Merck Sharp & Dohme B.V. Indane derivatives
PT2498610T (pt) * 2009-11-13 2018-06-19 Celgene Int Ii Sarl Moduladores seletivos de recetor de esfingosina 1 fosfato e métodos de síntese quiral
EP2498609B1 (en) * 2009-11-13 2018-04-18 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2011097337A1 (en) * 2010-02-04 2011-08-11 Advanced Neural Dynamics, Inc. Novel sulfamides exhibiting neuroprotective action and methods for use thereof
US20120077814A1 (en) * 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives

Also Published As

Publication number Publication date
KR20150032838A (ko) 2015-03-30
ES2628374T3 (es) 2017-08-02
RU2619937C2 (ru) 2017-05-22
CN104395285A (zh) 2015-03-04
CL2014003429A1 (es) 2015-03-27
PH12014502805A1 (en) 2015-02-23
KR101951519B1 (ko) 2019-02-22
US9018260B2 (en) 2015-04-28
LT2865663T (lt) 2017-07-10
SI2865663T1 (sl) 2017-07-31
RU2014151013A (ru) 2016-08-10
HUE033583T2 (hu) 2017-12-28
CA2877097A1 (en) 2013-12-27
IL236295A0 (en) 2015-02-26
ME02753B (me) 2018-01-20
PL2865663T3 (pl) 2017-09-29
HRP20170863T1 (hr) 2017-09-08
EP2865663B1 (en) 2017-04-05
ZA201409248B (en) 2015-12-23
EP2865663A4 (en) 2016-02-17
BR112014031565A8 (pt) 2021-06-08
HK1207363A1 (en) 2016-01-29
JP5883135B2 (ja) 2016-03-09
CA2877097C (en) 2018-08-07
CY1119171T1 (el) 2018-02-14
CN104395285B (zh) 2016-04-13
NZ702974A (en) 2016-03-31
AU2013278450B2 (en) 2017-04-20
BR112014031565B1 (pt) 2022-04-12
AR091506A1 (es) 2015-02-11
IL236295A (en) 2016-09-29
AU2013278450A1 (en) 2015-01-22
PE20150284A1 (es) 2015-02-21
MX355261B (es) 2018-04-12
US20140371319A1 (en) 2014-12-18
SG11201408359PA (en) 2015-01-29
TW201402530A (zh) 2014-01-16
TWI597263B (zh) 2017-09-01
MY169073A (en) 2019-02-13
MX2014015492A (es) 2015-05-08
RS56073B1 (sr) 2017-10-31
JPWO2013191144A1 (ja) 2016-05-26
PH12014502805B1 (en) 2015-02-23
WO2013191144A1 (ja) 2013-12-27
DK2865663T3 (en) 2017-06-19
JO3263B1 (ar) 2018-09-16
PT2865663T (pt) 2017-06-02
EP2865663A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
BR112014031565A2 (pt) derivado de indanossulfamida inovador
PH12017501306A1 (en) Inhibitors of histone demethylases
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
IN2014DN09434A (pt)
CR20140537A (es) Compuesto heterocíclico nitrogenado
PE20140255A1 (es) Tableta dispersable en forma oral
UA111148C2 (uk) Сигма-ліганди для застосування при профілактиці і/або лікуванні післяопераційного болю
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
WO2014153009A3 (en) Thiosaccharide mucolytic agents
WO2014144606A3 (en) Methods of treating muscular dystrophy
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2018005796A (es) Reduccion de la sensacion de picazon en la piel.
MY172807A (en) Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos
BR112014007177A2 (pt) agente antifúngico
MX370898B (es) Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
WO2014107685A3 (en) Compositions and methods for using huperzine and analogs thereof
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
IN2012DN00546A (pt)
BR112014028632A8 (pt) Composto, composição farmacêutica, e, método para preparar um composto
FR2989275B1 (fr) Principe actif a application cutanee obtenu a partir de metschnikowia agaves et utilisations pour ameliorer l'etat de la peau
JP2013071928A5 (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2013, OBSERVADAS AS CONDICOES LEGAIS.